Full-Spectrum Vitamin K (K1 + MK-4 + MK-7)
Full-spectrum vitamin K combines K1 (phylloquinone), MK-4, and MK-7 (menaquinones) to activate vitamin K-dependent proteins throughout the body. These compounds activate osteocalcin for bone mineralization and matrix Gla protein to prevent arterial calcification.
Origin & History
Full-Spectrum Vitamin K combines K1, MK-4, and MK-7 to provide comprehensive support for bone and cardiovascular health. These forms are derived from plant and bacterial sources.
Historical & Cultural Context
Vitamin K has been recognized for its role in blood clotting and bone health, with traditional uses in various cultures for maintaining cardiovascular health.
Health Benefits
- Supports bone health by activating proteins that bind calcium, crucial for preventing osteoporosis. - Enhances cardiovascular health by reducing arterial calcification, which can lower heart disease risk. - Supports cognitive function by reducing oxidative stress, potentially lowering the risk of Alzheimer's disease. - Aids in blood clotting, which is essential for wound healing and preventing excessive bleeding. - Promotes skin health by supporting collagen production, which is vital for maintaining elasticity and reducing wrinkles. - Supports joint health by reducing inflammation, which can alleviate arthritis symptoms. - Enhances metabolic health by improving insulin sensitivity, which can help manage diabetes risk.
How It Works
Vitamin K serves as a cofactor for gamma-glutamyl carboxylase, which activates vitamin K-dependent proteins by converting glutamic acid residues to gamma-carboxyglutamic acid. This process activates osteocalcin for calcium binding in bones and matrix Gla protein (MGP) to prevent soft tissue calcification. MK-7 shows superior bioavailability and longer half-life compared to K1, while MK-4 rapidly converts to menaquinone-4 in tissues.
Scientific Research
Studies suggest that combining different forms of vitamin K can enhance its benefits for bone density and cardiovascular health. Evidence supports its synergistic effects with vitamin D.
Clinical Summary
A 3-year randomized controlled trial of 244 postmenopausal women found 180 mcg daily MK-7 reduced bone loss and improved bone strength. Meta-analyses of vitamin K studies show 6-12% reduction in fracture risk with consistent supplementation. Cardiovascular studies indicate 90-360 mcg daily MK-7 for 12-36 months reduces arterial stiffness by 3-6%. Evidence is strongest for bone health, with emerging but promising data for cardiovascular benefits.
Nutritional Profile
Full-Spectrum Vitamin K is a fat-soluble vitamin supplement combining three primary forms: Phylloquinone (K1), Menaquinone-4 (MK-4), and Menaquinone-7 (MK-7). Typical formulations provide approximately 1,000–2,000 mcg Vitamin K1 (phylloquinone, derived from plant sources such as alfalfa or spinach extract), 1,000–1,500 mcg MK-4 (menaquinone-4, a short-chain menaquinone with rapid absorption but shorter half-life of ~2–4 hours), and 100–200 mcg MK-7 (menaquinone-7, a long-chain menaquinone typically derived from natto/Bacillus subtilis fermentation with a substantially longer half-life of ~72 hours, enabling sustained serum levels). Contains no significant macronutrients (protein, carbohydrates, fat, or fiber) per serving. Key bioactive compounds include the naphthoquinone ring structure common to all K vitamins, which serves as the essential cofactor for gamma-glutamyl carboxylase, activating vitamin K-dependent proteins (osteocalcin, matrix Gla protein, prothrombin, factors VII, IX, X, and proteins C and S). Bioavailability notes: All forms are fat-soluble and absorption is significantly enhanced (up to 3–8x) when taken with dietary fat (ideally 10–15 g). K1 bioavailability from supplements is approximately 80% (higher than from food sources at ~5–10% from green vegetables). MK-4 is rapidly absorbed but extensively metabolized, leading to a short duration of action. MK-7 has superior bioavailability and bioaccumulation due to its long half-life, achieving steady-state serum concentrations after ~2 weeks of daily dosing, and is more effective at carboxylating extrahepatic proteins (osteocalcin, MGP) at lower doses. MK-7 is approximately 2–3x more bioavailable than K1 on a microgram-per-microgram basis for extrahepatic tissue activation. Some formulations include medium-chain triglycerides (MCTs) or olive oil as carrier lipids to further enhance absorption. No significant mineral or additional vitamin content unless specifically fortified. The combination of all three forms provides both rapid hepatic support (K1 for coagulation) and sustained extrahepatic tissue benefits (MK-4 and MK-7 for bone and cardiovascular health).
Preparation & Dosage
Dosages typically include 100 mcg of K1, 100 mcg of MK-4, and 100 mcg of MK-7. Consult a healthcare provider before use.
Synergy & Pairings
Vitamin D3, Calcium, Magnesium
Safety & Interactions
Vitamin K can reduce warfarin effectiveness by promoting clotting factor synthesis, requiring careful monitoring in anticoagulated patients. Generally well-tolerated with no established upper intake limit, though doses above 1000 mcg may cause mild gastrointestinal upset. Contraindicated in individuals with known hypersensitivity to vitamin K compounds. Safe during pregnancy and breastfeeding at nutritional doses, but high-dose supplementation should be avoided without medical supervision.